Every 8-K that Aprea Therapeutics, Inc. (APRE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow APRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APRE filings page.
Aprea Therapeutics, Inc. (APRE) reported an expansion of its global intellectual property portfolio supporting its precision oncology programs. The company now has 28 issued and 30 pending patents across its pipeline. The WEE1 kinase inhibitor program, including lead asset APR-1051, is covered by two pending U.S. patent applications, one pending U.S. provisional, two granted non-U.S. patents in Australia and Korea, and 12 pending non-U.S. applications. This WEE1 family, if granted, would expire in 2047 and covers proprietary compounds, compositions, and methods of use.
The ATR inhibitor program, including ATRN-119, is protected by four granted U.S. patents, one pending U.S. application, one pending international application, 22 granted non-U.S. patents, and 13 pending non-U.S. applications, with granted patents expiring between 2035–2037 and potential extension to 2045 plus up to five years of regulatory exclusivities. Aprea previously set an RP2D of 1,100 mg once daily for ATRN-119 but closed that study to prioritize APR-1051, while considering ATRN-119 for future combination strategies.
Aprea Therapeutics, Inc. reported second quarter ended June 30, 2026 results and provided a business update centered on its lead oral WEE1 inhibitor APR-1051. Enrollment in the Phase 1 dose escalation ACESOT-1051 trial is accelerating, with plans to advance APR-1051 as a single agent in uterine serous carcinoma and Cyclin E–overexpressing platinum-resistant ovarian cancer, and in combination regimens in HPV-positive head and neck cancer and colorectal cancer. Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity, including partial responses and disease stabilization, with a manageable tolerability profile. The pipeline also includes ATR inhibitor ATRN-119 in clinical development for solid tumors.
Cash and cash equivalents were $41.2 million as of June 30, 2026, with total assets of $42.3 million and stockholders’ equity of $38.5 million. For the quarter, Aprea reported a net loss of $3.6 million on operating expenses of $4.0 million, primarily research and development of $2.5 million and general and administrative of $1.6 million. Six-month net loss was $6.9 million. Weighted-average basic and diluted common shares outstanding for the quarter were 53.5 million.
Aprea Therapeutics, Inc. received a notification from Nasdaq on July 23, 2026 that it qualifies for an additional 180-day Second Compliance Period, through January 19, 2027, to regain compliance with the Nasdaq Capital Market Minimum Bid Price Requirement of at least $1.00 per share under Listing Rule 5550(a)(2).
The company had previously been given until July 22, 2026 to restore compliance after its common stock fell below the $1.00 minimum bid price. If at any time during the Second Compliance Period the closing bid price of the common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will confirm compliance. If compliance is not demonstrated by January 19, 2027, Nasdaq states it will issue a notice of delisting, which Aprea could then appeal to a hearings panel.
Aprea Therapeutics, Inc. reported results of its 2026 annual stockholder meeting. Of 12,382,776 common shares entitled to vote, 8,268,451 shares, or approximately 66.8%, were represented, establishing a quorum.
Stockholders elected three Class I directors—Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.—to serve until the 2029 annual meeting or until successors are elected and qualified. EisnerAmper LLP was ratified as independent registered public accounting firm for fiscal year 2026.
Stockholders approved an amendment to the certificate of incorporation authorizing the board to implement a reverse stock split at a ratio between one-for-three and one-for-eight, with the exact ratio and timing left to the board’s discretion. They also approved, on a non-binding basis, executive compensation and, by advisory vote, indicated a preference for annual say-on-pay votes. An adjournment proposal related to the reverse split was also approved.
Aprea Therapeutics reported first quarter 2026 results and highlighted progress in its oncology pipeline. The company is evaluating APR-1051 in the ACESOT-1051 Phase 1 trial, where two partial responses were observed, one of which was confirmed and remains on study. A recent $30 million private placement strengthened the balance sheet and is expected to support expanded enrollment for APR-1051.
Cash and cash equivalents rose to $46.5 million as of March 31, 2026, up from $14.6 million at December 31, 2025, which the company believes will fund operations into the first quarter of 2028. Aprea posted an operating loss of $3.4 million, down from $4.1 million a year earlier, and a net loss of $3.3 million, or ($0.22) per share, versus $3.9 million, or ($0.66) per share, in the prior-year quarter.
Aprea Therapeutics, Inc. closed an oversubscribed private placement, raising total gross proceeds of approximately $30 million. The funding comes from a group led by Soleus Capital, with new and existing investors and certain insiders participating.
The company issued pre-funded warrants to purchase up to about 37.2 million shares of common stock and additional warrants to purchase up to about 37.2 million shares. Warrant exercise prices range around $0.808 and $0.683 per share. Aprea plans to use net proceeds for general corporate purposes and to advance development of its lead WEE1 inhibitor APR-1051, including expanding its ACESOT-1051 study into selected biomarker-defined tumor populations.
Aprea Therapeutics, Inc. entered into a securities purchase agreement for an oversubscribed private placement expected to raise approximately $30 million in gross proceeds through pre-funded warrants and common stock warrants for up to about 37.2 million shares each. The warrants are priced at a purchase price of $0.808 per pre-funded warrant, with a common warrant exercise price of $0.683 per share. Aprea plans to use the upfront net proceeds for general corporate purposes and research and development and currently expects this funding to extend its cash runway into the first quarter of 2028. The company also reported a confirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer, along with additional stable disease cases, supporting early signs of anti-tumor activity.
Aprea Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided a corporate update. For 2025, grant revenue was $285,759, down from $1,502,581 in 2024, reflecting lower non-dilutive funding.
Total operating expenses for 2025 were $13,519,595, compared with $15,822,236 in 2024, driven by lower research and development spending of $7,043,035 and relatively stable general and administrative costs of $6,476,560. Net loss for 2025 was $12,599,569, slightly improved from $12,958,711 in 2024, with net loss per share narrowing to $1.93 from $2.35.
On the balance sheet, total assets at December 31, 2025 were $15,933,401, down from $23,979,493 a year earlier, including cash and cash equivalents of $14,599,347. The company highlighted progress in its WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119 programs and noted recent private placements that strengthened its balance sheet, while emphasizing its focus on targeted therapies for biomarker-defined cancers.
Aprea Therapeutics reported new early clinical signals for its WEE1 inhibitor APR-1051 from the ongoing Phase 1 ACESOT-1051 trial in advanced solid tumors. A second unconfirmed partial response was seen in a patient with advanced endometrial cancer at the 220 mg dose, showing a 50% reduction in target lesions and an 87% drop in CA-125, from 362 U/mL to 47 U/mL. The tumor carries a PPP2R1A mutation, and the patient has only experienced Grade 1 treatment-emergent side effects and remains on therapy. Across the study, 22 patients have been treated at doses from 10 mg to 220 mg, and a further trial update is planned for the second quarter of 2026.
Aprea Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 6,288,857 shares of common stock or pre-funded warrants, together with common stock warrants to purchase up to 6,288,857 shares. The combined effective offering price per share or pre-funded warrant plus accompanying warrant is $0.89, for expected aggregate gross proceeds of approximately $5.6 million.
The common warrants have a $0.765 exercise price, a two-year term starting after resale registration effectiveness or Rule 144 eligibility, and 4.99% or 9.99% ownership caps, with cashless exercise allowed in certain cases. Aprea agreed to file and maintain a resale registration statement and accepted issuance and variable-rate financing restrictions for defined periods. Maxim Group LLC will receive a 7% cash fee on gross proceeds and reimbursement of up to $35,000 in expenses. The company also reported a first unconfirmed partial response in its ongoing Phase 1 ACESOT-1051 study and updated its corporate presentation.
Aprea Therapeutics, Inc. reported that it received a deficiency letter from Nasdaq because its common stock has closed below the required $1.00 minimum bid price for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The notice does not immediately affect trading, and the stock will continue to trade on The Nasdaq Capital Market under the symbol APRE.
The company has 180 calendar days, until July 22, 2026, to regain compliance by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If it still meets other listing standards, it may qualify for a second 180-day period. If compliance is not regained, the stock could be delisted, although the company would have the right to appeal. Aprea is monitoring its share price and may consider actions such as a reverse stock split, but there is no assurance it will meet the minimum bid price or other Nasdaq rules.
Aprea Therapeutics, Inc. filed a current report to note that it has updated its corporate presentation slide deck as of January 9, 2026. The refreshed investor presentation is included as Exhibit 99.1 and is incorporated by reference, meaning it is treated as part of the official disclosure record. The filing does not describe the specific changes to the presentation, only that a new January 2026 version is now available.
Aprea Therapeutics, Inc. furnished a press release announcing financial results for the three and nine months ended September 30, 2025, and provided an operations update. The release is attached as Exhibit 99.1.
The company also filed an updated corporate presentation as Exhibit 99.2. Per General Instruction B.2, the Item 2.02 information, including Exhibit 99.1, is furnished and not deemed filed under Section 18, nor incorporated by reference unless expressly stated.
Aprea Therapeutics (APRE) reported an other event, stating it issued a press release with a clinical update from the ACESOT-1051 trial that shows early signals of activity for its WEE1 kinase inhibitor, APR-1051.
The press release is attached as Exhibit 99.1 and incorporated by reference. This notice informs the market of new clinical observations; detailed results and context are contained in the attached press release.
Aprea Therapeutics (APRE) reported operational updates via Form 8-K. The company announced the recommended Phase 2 dosing for ATRN-119, paused further enrollment in both once-daily and twice-daily dosing arms of ABOYA-119, and is considering additional ATRN-119 development in combination therapies.
The updates were communicated in a press release dated October 15, 2025, and accompanied by a refreshed corporate presentation. Both materials are provided as exhibits to the filing, offering more detail on current development plans and clinical program status.
Aprea Therapeutics, Inc. filed a Form 8-K to report that it updated its corporate presentation slide deck on September 8, 2025. The updated investor presentation, dated September 2025, is included as Exhibit 99.1 and incorporated by reference. This is a routine corporate communication intended to provide updated information about the company to investors and other stakeholders.
Aprea Therapeutics furnished a press release that announces its financial results for the three- and six-month periods ended June 30, 2025 and provided an operational update. The press release is attached as Exhibit 99.1 and the company also updated its corporate presentation, filed as Exhibit 99.2. The Form 8-K states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K itself does not include the underlying financial figures or metrics; it notifies investors that the detailed results and presentation materials are available in the referenced exhibits.